Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

More than 40 years after the first AIDS cases, new long-acting drugs and antibody-based therapies are reviving hopes that HIV ...

HIV remains a major global health issue, affecting nearly 40 million people worldwide. Current treatments, known as ...

In what may be one of the most important HIV research breakthroughs in years, scientists have discovered a strikingly ...

Human immunodeficiency viruses (HIV) are insidious. They can evade the immune defense and antiviral drugs by becoming "latent ...

A new study led by researchers at the George Washington University and published through the DC Cohort, one of the largest HIV longitudinal studies in the United States, finds that nearly half of ...

A new five-year, $17 million research award has been used to fund and launch Wistar’s new iCure Consortium. The goal of the ...

Lenacapavir has the potential to end the HIV epidemic, researchers say. The Trump administration says backing this kind of ...

Cuts proposed by the Trump administration and House Republicans could drive up new HIV cases by more than 200,000 by 2030, ...

The Memphis area now ranks first in the nation for new HIV infections, according to local health officials. But a global ...

South Africa's health minister has called lenacapavir, the first twice-yearly HIV prevention jab, a "groundbreaking" tool ...